Pola-RCHP with or without extra drug for untreated DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding a targeted drug (X) to the standard Pola-R-CHP regimen works better for people with DLBCL whose cancer didn't respond well after the first cycle of chemo. It compares the standard treatment to a combination with an extra drug, aiming to improve outcomes for those who need it most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with CD20-positive diffuse large B-cell lymphoma (DLBCL) and have not had any prior treatment for it.
- Your IPI score (a measure of how aggressive the lymphoma might be) is between 2 and 5.
- Your performance status is 0, 1, or 2 (meaning you can still take care of yourself and do light activities).
- After one cycle of standard treatment (Pola-R-CHP), a blood test showed that your lymphoma DNA levels did not drop enough (less than 3-fold decrease).
- You have adequate heart, blood, kidney, and liver function, and no other serious health conditions that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This study compares three different drug combinations for people with untreated DLBCL. One group gets a standard combination (pola-RCHP), another gets that plus a targeted pill (like orelabrutinib or venetoclax), and a third gets the standard chemo without the targeted antibody. The goal is to see which approach works best and is safest.
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
This trial tests a combination of two targeted therapies, polatuzumab vedotin and glofitamab, for people with DLBCL that either came back within 12 months of R-CHOP or never went away. The goal is to see if this two-drug approach can help when standard chemotherapy has not worked well.
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.